Suppression of the invasion and migration of cancer cells by SERPINB family genes and their derived peptides

Oncology Reports

Volumn 27, Issue 1, 2012, Pages 238-245

  Chou, Ruey Hwang ^a,b,c,d   Wen, Hui Chin ^a   Liang, Wei Guang ^a,e   Lin, Sheng Chieh ^a,e   Yuan, Hsiao Wei ^a   Wu, Cheng Wen ^a,e,f   Chang, Wun Shaing Wayne ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d ASIA UNIVERSITY   (Taiwan)

^e NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^f NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Cancer; Invasion; Migration; SERPINB family

Indexed keywords

SERINE PROTEINASE B INHIBITOR REACTIVE CENTER LOOP DERIVED PEPTIDE; SERINE PROTEINASE B1 INHIBITOR REACTIVE CENTER LOOP DERIVED PEPTIDE; SERINE PROTEINASE B5 INHIBITOR REACTIVE CENTER LOOP DERIVED PEPTIDE; SERINE PROTEINASE B7 INHIBITOR REACTIVE CENTER LOOP DERIVED PEPTIDE; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CANCER TISSUE; CELL INVASION; CELL MOTILITY; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; DRUG SYNTHESIS; GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUNG CANCER; MIGRATION INHIBITION; PRIORITY JOURNAL; SERPINB GENE; SERPINB1 GENE; SERPINB5 GENE; SERPINB7 GENE; UPREGULATION;

CELL LINE, TUMOR; CELL MOVEMENT; HUMANS; NEOPLASM INVASIVENESS; NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SERPINS;

EID: 84855289000     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1497     Document Type: Article

References (44)

1. Chaffer CL and Weinberg RA: A perspective on cancer cell metastasis. Science 331: 1559-1564, 2011.
2. Andreasen PA, Egelund R and Petersen HH: The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 57: 25-40, 2000. (Pubitemid 30105328)
3. Hildenbrand R, Allgayer H, Marx A and Stroebel P: Modulators of the urokinase-type plasminogen activation system for cancer. Expert Opin Investig Drugs 19: 641-652, 2010.
4. Deryugina EI and Quigley JP: Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25: 9-34, 2006. (Pubitemid 43723979)
5. Gettins PG: Serpin structure, mechanism, and function. Chem Rev 102: 4751-4804, 2002.
6. Silverman GA, Bird PI, Carrell RW, et al: The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem 276: 33293-33296, 2001.
7. Izuhara K, Ohta S, Kanaji S, Shiraishi H and Arima K: Recent progress in understanding the diversity of the human ov-serpin/clade B serpin family. Cell Mol Life Sci 65: 2541-2553, 2008.
8. Nakamura M, Konno H, Tanaka T, et al: Possible role of plasminogen activator inhibitor 2 in the prevention of the metastasis of gastric cancer tissues. Thromb Res 65: 709-719, 1992.
9. Ito H, Yonemura Y, Fujita H, et al: Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer. Virchows Arch 427: 487-496, 1996. (Pubitemid 126828180)
10. Ishikawa N, Endo Y and Sasaki T: Inverse correlation between mRNA expression of plasminogen activator inhibitor-2 and lymph node metastasis in human breast cancer. Jpn J Cancer Res 87: 480-487, 1996. (Pubitemid 26182318)
11. Yoshino H, Endo Y, Watanabe Y and Sasaki T: Significance of plasminogen activator inhibitor 2 as a prognostic marker in primary lung cancer: association of decreased plasminogen activator inhibitor 2 with lymph node metastasis. Br J Cancer 78: 833-839, 1998. (Pubitemid 28418323)
12. Mueller BM, Yu YB and Laug WE: Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in scid/scid mice. Proc Natl Acad Sci USA 92: 205-209, 1995.
13. Chen EI and Yates JR: Maspin and tumor metastasis. IUBMB Life 58: 25-29, 2006.
14. Marioni G, Staffieri C, Staffieri A, De Filippis C and Blandamura S: MASPIN tumour-suppressing activity in head and neck squamous cell carcinoma: emerging evidence and therapeutic perspectives. Acta Otolaryngol 129: 476-480, 2009.
15. Lonardo F, Li X, Kaplun A, et al: The natural tumor suppressor protein maspin and potential application in non-small cell lung cancer. Curr Pharm Des 16: 1877-1881, 2010.
16. Stenman J, Hedstrom J, Grenman R, et al: Relative levels of SCCA2 and SCCA1 mRNA in primary tumors predicts recurrent disease in squamous cell cancer of the head and neck. Int J Cancer 95: 39-43, 2001.
17. Nakashima T, Pak SC, Silverman GA, Spring PM, Frederick MJ and Clayman GL: Genomic cloning, mapping, structure and promoter analysis of HEADPIN, a serpin which is down-regulated in head and neck cancer cells. Biochim Biophys Acta 1492: 441-446, 2000. (Pubitemid 30427356)
18. Moussali H, Bylaite M, Welss T, Abts HF, Ruzicka T and Walz M: Expression of hurpin, a serine proteinase inhibitor, in normal and pathological skin: overexpression and redistribution in psoriasis and cutaneous carcinomas. Exp Dermatol 14: 420-428, 2005. (Pubitemid 40740393)
19. Walz M, Kellermann S, Bylaite M, et al: Expression of the human Cathepsin L inhibitor hurpin in mice: skin alterations and increased carcinogenesis. Exp Dermatol 16: 715-723, 2007. (Pubitemid 47261862)
20. Shiiba M, Nomura H, Shinozuka K, et al: Down-regulated expression of SERPIN genes located on chromosome 18q21 in oral squamous cell carcinomas. Oncol Rep 24: 241-249, 2010.
21. Chou RH, Lin KC, Lin SC, Cheng JY, Wu CW and Chang WS: Cost-effective trapezoidal modified Boyden chamber with comparable accuracy to a commercial apparatus. Biotechniques 37: 724-726, 2004.
22. Smith SL, Watson SG, Ratschiller D, Gugger M, Betticher DC and Heighway J: Maspin - the most commonly-expressed gene of the 18q21.3 serpin cluster in lung cancer - is strongly expressed in preneoplastic bronchial lesions. Oncogene 22: 8677-8687, 2003. (Pubitemid 38010491)
23. Maass N, Hojo T, Rosel F, Ikeda T, Jonat W and Nagasaki K: Down-regulation of the tumor suppressor gene maspin in breast carcinoma is associated with a higher risk of distant metastasis. Clin Biochem 34: 303-307, 2001. (Pubitemid 32607573)
24. Pellegrin P, Fernandez A, Lamb NJ and Bennes R: Macromolecular uptake is a spontaneous event during mitosis in cultured fibroblasts: implications for vector-dependent plasmid transfection. Mol Biol Cell 13: 570-578, 2002. (Pubitemid 34165084)
25. Baker MS, Bleakley P, Woodrow GC and Doe WF: Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation. Cancer Res 50: 4676-4684, 1990. (Pubitemid 20230412)
26. Li Y, Rizvi SM, Ranson M and Allen BJ: 213Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model. Br J Cancer 86: 1197-1203, 2002. (Pubitemid 34438096)
27. Abbas Rizvi SM, Li Y, Song EY, et al: Preclinical studies of bismuth-213 labeled plasminogen activator inhibitor type 2 (PAI2) in a prostate cancer nude mouse xenograft model. Cancer Biol Ther 5: 386-393, 2006.
28. Qu CF, Song EY, Li Y, et al: Pre-clinical study of 213Bi labeled PAI2 for the control of micrometastatic pancreatic cancer. Clin Exp Metastasis 22: 575-586, 2005. (Pubitemid 43234642)
29. Song YJ, Qu CF, Rizvi SM, et al: Cytotoxicity of PAI2, C595 and Herceptin vectors labeled with the alpha-emitting radioisotope Bismuth-213 for ovarian cancer cell monolayers and clusters. Cancer Lett 234: 176-183, 2006.
30. Sheng S, Truong B, Fredrickson D, Wu R, Pardee AB and Sager R: Tissue-type plasminogen activator is a target of the tumor suppressor gene maspin. Proc Natl Acad Sci USA 95: 499-504, 1998. (Pubitemid 28083771)
31. Biliran H Jr and Sheng S: Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin. Cancer Res 61: 8676-8682, 2001. (Pubitemid 34013876)
32. Sun J, Coughlin P, Salem HH and Bird P: Production and characterization of recombinant human proteinase inhibitor 6 expressed in Pichia pastoris. Biochim Biophys Acta 1252: 28-34, 1995.
33. Miyata T, Inagi R, Nangaku M, et al: Overexpression of the serpin megsin induces progressive mesangial cell proliferation and expansion. J Clin Invest 109: 585-593, 2002. (Pubitemid 34204837)
34. Askew YS, Pak SC, Luke CJ, et al: SERPINB12 is a novel member of the human ov-serpin family that is widely expressed and inhibits trypsin-like serine proteinases. J Biol Chem 276: 49320-49330, 2001.
35. Cooley J, Takayama TK, Shapiro SD, Schechter NM and Remold-O'Donnell E: The serpin MNEI inhibits elastase-like and chymotrypsin-like serine proteases through efficient reactions at two active sites. Biochemistry 40: 15762-15770, 2001. (Pubitemid 34015205)
36. Shamamian P, Schwartz JD, Pocock BJ, et al: Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase-3: a role for inflammatory cells in tumor invasion and angiogenesis. J Cell Physiol 189: 197-206, 2001. (Pubitemid 32946031)
37. Obermajer N, Jevnikar Z, Doljak B and Kos J: Role of cysteine cathepsins in matrix degradation and cell signalling. Connect Tissue Res 49: 193-196, 2008.
38. Le Gall C, Bonnelye E and Clezardin P: Cathepsin K inhibitors as treatment of bone metastasis. Curr Opin Support Palliat Care 2: 218-222, 2008.
39. Katunuma N, Tsuge H, Nukatsuka M and Fukushima M: Structure-based development of cathepsin L inhibitors and therapeutic applications for prevention of cancer metastasis and cancer-induced osteoporosis. Adv Enzyme Regul 42: 159-172, 2002. (Pubitemid 35033536)
40. Rousselet N, Mills L, Jean D, Tellez C, Bar-Eli M and Frade R: Inhibition of tumorigenicity and metastasis of human melanoma cells by anti-cathepsin L single chain variable fragment. Cancer Res 64: 146-151, 2004. (Pubitemid 38114092)
41. Schick C, Pemberton PA, Shi GP, et al: Cross-class inhibition of the cysteine proteinases cathepsins K, L, and S by the serpin squamous cell carcinoma antigen 1: a kinetic analysis. Biochemistry 37: 5258-5266, 1998. (Pubitemid 28176527)
42. Schick C, Bromme D, Bartuski AJ, Uemura Y, Schechter NM and Silverman GA: The reactive site loop of the serpin SCCA1 is essential for cysteine proteinase inhibition. Proc Natl Acad Sci USA 95: 13465-13470, 1998. (Pubitemid 28522995)
43. Jayakumar A, Kang Y, Frederick MJ, et al: Inhibition of the cysteine proteinases cathepsins K and L by the serpin headpin (SERPINB13): a kinetic analysis. Arch Biochem Biophys 409: 367-374, 2003. (Pubitemid 36259605)
44. Ngamkitidechakul C, Warejcka DJ, Burke JM, O'Brien WJ and Twining SS: Sufficiency of the reactive site loop of maspin for induction of cell-matrix adhesion and inhibition of cell invasion. Conversion of ovalbumin to a maspin-like molecule. J Biol Chem 278: 31796-31806, 2003. (Pubitemid 37048361)